Accellix Appoints Dr. Félix A. Montero-Julian as Vice President of Scientific Affairs
Accellix, a global leader in rapid point of need cytometry solutions, is pleased to announce the appointment of Félix A. Montero-Julian, PhD as Vice President of Scientific Affairs. Dr. Montero-Julian brings more than 30 years of international experience in scientific affairs, analytical development, and regulatory science to support Accellix’s strategic vision and innovation roadmap.
Dr. Montero-Julian joins Accellix from bioMérieux, where he most recently served as Scientific Senior Director of Pharma Quality Control. His previous roles include Cytometry R&D Director at bioMérieux and Director of the Cellular Analysis Department at Beckman Coulter, underscoring a distinguished track record spanning biopharmaceuticals, industrial microbiology, and clinical diagnostics.
“I’m excited to join Accellix during this period of dynamic growth and innovation,” said Dr. Montero-Julian. “I have great confidence in the potential of the Accellix Platform to transform quality control in cell and gene therapy manufacturing and blood characterization. I look forward to collaborating closely with this exceptional team to accelerate innovation and drive meaningful impact for our partners and the patients they serve."
Dr. Montero-Julian holds a PhD and Master of Science in Immunology from Aix-Marseille II University in France, and a degree in Industrial Biochemistry Engineering from Universidad Autónoma Metropolitana in Mexico. He has also completed executive coursework in business development, quality systems, and regulatory affairs. A respected thought leader in the development and regulatory acceptance of analytical methods for advanced therapeutics and biomanufacturing, he has authored more than 60 scientific publications.
“We are honored to welcome Félix to the Accellix leadership team,” said Greg Hamilton, CEO of Accellix. “His deep scientific knowledge and leadership experience across cytometry, regulatory science, and pharmaceutical QC make him uniquely qualified to shape our scientific strategy and partnerships as we scale the impact of the Accellix Platform.”
As Vice President of Scientific Affairs, Dr. Montero-Julian will lead Accellix’s scientific engagement strategy, drive cross-functional collaboration across R&D, regulatory, and commercial teams, and help advance the company’s mission to make rapid, automated cytometry accessible and reliable for blood collection centers and cell therapy manufacturers.
ABOUT ACCELLIX
Accellix is a biotechnology company dedicated to developing and commercializing the Accellix Platform to enable its customers in the field of cell and gene therapy and blood characterization to meet their critical QC requirements as they advance life changing therapies benefiting patients worldwide. Accellix empowers its customers by migrating their existing cell phenotyping assays to the Accellix Platform. The Accellix Platform is a benchtop cytometer operating and reading capillary cartridges integrated with dry reagents. It provides unmatched reproducibility and ease of use for automated multi-parametric cell analysis. For more information visit www.accellix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250707760393/en/
Contacts
Efthalia Gerasimopoulos
egerasimopoulos@accellix.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tecnotree Recognized in Two 2025 Gartner ® Hype Cycle™ Reports7.7.2025 17:46:00 EEST | Press release
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, has been recognized in two 2025 Gartner® Hype Cycle™ reports. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250707226738/en/ Tecnotree Recognized in Two 2025 Gartner® Hype Cycle™ Tecnotree has been recognized in the following 2025 Gartner Hype Cycle reports: Hype Cycle for Enterprise Communication Services, 2025 for CSP Digital MarketplacesHype Cycle for Operations and Automation in the Communications Industry, 2025 for Partner Ecosystem Management Platforms for CSPs and AI for CSP Customer Interactions We believe that this recognition highlights Tecnotree’s commitment to accelerating CSPs’ digital transformation journeys by offering composable, AI-driven solutions that enable ecosystem monetization, automated customer interactions, and next-gen partner management. These capabilities are part of the Tecnotree Moments and Tecn
Zycus Named a LEADER in 2025 IDC MarketScape for Source-to-Pay7.7.2025 16:41:00 EEST | Press release
Zycus, a global leader in AI-powered procurement technology, has been named a Leader in the IDC MarketScape: Worldwide AI-Enabled Source-to-Pay 2025 Vendor Assessment. This recognition follows a comprehensive evaluation, including RFI submissions, live product demos, analyst briefings, and customer interviews. “Zycus is a recognized Leader in the Source-to-Pay space leveraging Agentic AI to drive procurement transformation. With AI agents like Merlin Intake and the Autonomous Negotiation Agent (ANA), Zycus offers a seamlessly integrated solution suite for enterprises focused on cost savings, risk mitigation, and scalability,” — Patrick Reymann, Research Director, IDC “We believe this recognition underscores our commitment to empowering procurement teams through Merlin Agentic Platform, deep domain expertise, and customer-first innovation,” said Aatish Dedhia, Founder & CEO, Zycus. “With a global product footprint spanning every aspect of the S2P lifecycle, Zycus is proud to support ent
Kevin Egan Joins ClickHouse as Chief Revenue Officer to Accelerate Growth7.7.2025 16:00:00 EEST | Press release
ClickHouse, a leader in real-time analytics, data warehousing, observability, and AI/ML, today announced the appointment of Kevin Egan as Chief Revenue Officer (CRO). With over two decades of experience building and leading enterprise sales organizations at Atlassian, Slack, Dropbox, and Salesforce, Egan will oversee ClickHouse’s global go-to-market functions as demand continues to grow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250707959780/en/ Aaron Katz, ClickHouse CEO with Kevin Egan, ClickHouse CRO “I’m incredibly excited to join ClickHouse at such a pivotal time,” said Egan. “As organizations navigate how to compete and thrive in the AI era, ClickHouse is emerging as the de facto database powering the real-time, scalable analytics that AI-driven applications demand. I look forward to building strong relationships not only with forward-thinking customers, but also with our channel and technology partners—working to
NTT DATA Appoints Anne-Sophie Lotgering as Europe CEO7.7.2025 14:00:00 EEST | Press release
NTT DATA, a global leader in digital business and technology services, today announced the appointment of Anne-Sophie Lotgering as the new Chief Executive Officer for Europe at NTT DATA, Inc., effective 1 September 2025. Lotgering succeeds Chieri Kimura and will report directly to NTT DATA, Inc. President and Global CEO, Abhijit Dubey. She will also join NTT DATA, Inc.’s Executive Leadership Team. Lotgering brings over two decades of leadership experience in IT services and telecommunications, with a strong track record in B2B2C and B2B sales, digital marketing and transformation. She joins NTT DATA from Proximus NXT IT where she served as CEO, overseeing the IT integration of B2B operations across the Netherlands, Luxembourg, and Belgium. Her recent achievements include the successful unification of multiple subsidiaries into a single, agile organization, strategically aligned with high-growth sectors such as cloud, cybersecurity and data. Her career spans senior roles at The Orange G
CorFlow Therapeutics Announces FDA Approval of the MOCA-II IDE Pivotal Trial to Validate a Novel Heart Attack Care Technology7.7.2025 14:00:00 EEST | Press release
CorFlow Therapeutics AG (CorFlow), a pioneering company in the field of cardiac care targeting microvascular disease, today announced that the U.S. Food & Drug Administration (FDA) has approved the company’s technology for investigational device exemption (IDE), which allows the pivotal clinical trial to begin at U.S. hospitals. CorFlow will now prepare these clinical trial sites to receive CorFlow systems, undergo training and begin enrolling patients being treated for heart attacks. The IDE Pivotal Trial, MOCA-II, is intended to prospectively validate the diagnostic accuracy of the proprietary CorFlow CoFl system in determining the presence or absence of microvsacular obstruction (MVO) during a primary PCI procedure. The primary endpoint compares the CoFI diagnostic reading to a reference standard of diagnosis by a cardiac MRI scan. The trial is approved to enroll over 200 STEMI patients at prestigious research institutions in both the United States and Europe. Having successfully co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom